Gabrielle MassonJournalist
FierceBiotech and 1 other title
Health & social care coverage read by Vital Signs
3 articles
Across 2 topics, first on 20 Jan 2026, most recently 9 Sept 2026.
This counts only pieces our coverage scan read on the topics Vital Signs tracks, not their full output.
What they cover
Who they quote
Voices credited in their pieces. A reporter who has called someone before is likely to call them again.
- Bijan Nejadnik, M.D.Sector leader1 article
- Christelle Huguet, Ph.D.Sector leader1 article
Recent articles
- Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail
FierceBiotechRare diseases
- Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
BioSpaceHeart disease & stroke9 Sept 2026
- Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark
FierceBiotechRare diseases20 Jan 2026
Bylines and quoted sources are read automatically from UK coverage of the topics Vital Signs tracks, so this page reflects what our scan has read rather than a complete record. Where a biography and photograph appear, they are published by the outlet itself about its own correspondent, and linked above. Social accounts are not held: asserting an unverified one would attach a real person to an account that might not be theirs. See the methodology, or email contact@bridgeheadcommunications.com to correct anything on it.